Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort study



Lewis, J ORCID: 0000-0002-3837-5188, Smith, C, Torkington, A, Davies, C, Ahmad, S, Tomkins, A, Shaw, J, Kingston, M, Muqbill, G, Hay, P
et al (show 8 more authors) (2016) Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort study. , England.

[img] Text
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom A multicentre retrospective cohort study.pdf - Published version

Download (913kB) | Preview

Abstract

<h4>Objectives</h4>Persistence with an antiretroviral therapy (ART) regimen for HIV can be defined as the length of time a patient remains on therapy before stopping or switching. We aimed to describe ART persistence in treatment naïve patients starting therapy in the United Kingdom, and to describe differential persistence by treatment regimen.<h4>Methods</h4>We performed a retrospective cohort study at eight UK centres of ART-naïve adults commencing ART between 2012 and 2015. Aggregate data were extracted from local treatment databases. Time to discontinuation was compared for different third agents and NRTI backbones using incidence rates.<h4>Results</h4>1949 patients contributed data to the analysis. Rate of third agent change was 28 per 100 person-years of follow up [95% CI 26-31] and NRTI backbone change of 15 per 100 person-years of follow up [95% CI 14-17]). Rilpivirine, as co-formulated rilpivirine/tenofovir/emtricitabine had a significantly lower discontinuation rate than all other third agents and, excluding single tablet regimens, co-formulated tenofovir/emtricitabine had a significantly lower discontinuation rate than co-formulated abacavir/lamivudine. The reasons for discontinuation were not well recorded.<h4>Conclusions</h4>Treatment discontinuation is not an uncommon event. Rilpivirine had a significantly lower discontinuation rate than other third agents and tenofovir/emtricitabine a lower rate than co-formulated abacavir/lamivudine.

Item Type: Conference or Workshop Item (Unspecified)
Uncontrolled Keywords: Humans, HIV-1, HIV Infections, Deoxycytidine, Lamivudine, Dideoxynucleosides, Drug Combinations, Anti-HIV Agents, CD4 Lymphocyte Count, Viral Load, Retrospective Studies, Cohort Studies, Adult, Middle Aged, Female, Male, Medication Adherence, Tenofovir, Emtricitabine, Rilpivirine, United Kingdom
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Infection, Veterinary and Ecological Sciences
Depositing User: Symplectic Admin
Date Deposited: 12 Jan 2022 15:24
Last Modified: 18 Jan 2023 21:16
DOI: 10.1016/j.jinf.2017.01.012
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3146682